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1. SUMMARY (ENG) 
Malignant skin melanoma is at its advanced stage highly aggressive and 
chemoresistant to almost all currently available thrapies. Moderns efforts are thus 
aimed to identify new targets in melanoma cells or t  take advantage of novel 
indications of already approved drugs – a process called drug repurposing. This work 
was focused on evaluation of cell growth inhibitory properties of one such drug – 
flubendazole (FLU) – a widely used anthelmintic comp und belonging to 
benzimidazole family. This drug specifically interacts with β-tubulin, which results in 
disruption of microtubule structure and function in the exposed cells. Several members 
of the benzimidazole family (including FLU) have already shown the growth inhibitory 
potential in tumor cells derived from breast, colon, blood and nervous system 
malignancies. Still, the specific activity of FLU in malignant melanoma has not been 
tested to the date. 
Cytotoxicity of FLU was tested in three malignant melanoma cell lines 
representing diverse melanoma molecular types (A-375, BOWES and RPMI-7951) 
during up to 72 hours using WST-1 and x-CELLigence assays. Based on achieved IC50 
from individual cell lines, the 1 µM FLU concentration was selected for further testing. 
While relatively tolerated in normal human skin melanocytes, FLU at this concentration 
disrupted microtubular cytoskeleton, induced G2/M cell cycle arrest and changed 
morphology of exposed melanoma cells. The presence of other specific changes (i.e. 
cell enlargement and multinucleation, overexpression of p21 and activation of 
caspase-2) indicated mitotic catastrophe which was followed by apoptotic cell death. 
Further analyses revealed that both processes were not linked by activated TP53-BAX 
axis and their further elucidation should be addressed in future. 
FLU activity was also evaluated in melanoma cells derived from melanoma 
explant cultures obtained from human subjects undergoing melanoma excision in 
Faculty teaching hospital in Hradec Králové. In a pilot study using cells from one 
patient FLU showed cytotoxicity and growth inhibitory properties, however, with lesser 
potency as judged from higher IC50 value. 1 µM FLU concentration then had cytostatic 
effect in exposed cells and induced a series of very unusual morphological alterations 




2. SUMMARY (CZE) 
Maligní kožní melanom je ve svém pokročilém stádiu vysoce agresivním 
nádorovým onemocně ím často chemorezistentním na většinu současných 
terapeutických strategií. V současné době se výzkumy zaměřují na identifikaci nových 
cílů v maligních melanocytech či se snaží využít tzv. nových indikací již schválených 
léčiv, a to prostřednictvím přístupů nazývaných „drug repurposing“. Tato práce se 
zabývá ověřováním růstově inhibičních vlastností jednoho takového léčiva – 
flubendazolu (FLU) – široce využívaného anthelmintika patřícího do rodiny 
benzimidazolových derivátů. Toto léčivo specificky interaguje s β-tubulinem, což 
následně vede k poškození struktury a funkce mikrotubulů v ovlivněných buňkách. 
Několik členů benzimidazolové rodiny (včetně FLU) již prokázalo růstově-inhibiční 
potenciál u nádorových buněk odvozených z nádorů prsu, tlustého střeva, krve a 
nervového systému. Protinádorové vlastnosti FLU u maligního melanomu však ještě do 
této doby nebyly ověřovány. 
Cytotoxicita FLU byla testována u tří linií lidského maligního melanomu 
představující odlišné molekulární subtypy (A-375, BOWES a RPMI-7951) během 
72 hodin pomocí WST-1 a x-CELLigence testů. Na základě jednotlivých hodnot IC50 
získaných z jednotlivých buněčných linií byla pro další testování vybrána koncentrace 
FLU 1 µM. Tato koncentrace byla relativně tolerována u normálních lidských kožních 
melanocytů (HEM), nicméně u melanomových buněk významně poškodila organizaci a 
funkci mikrotubulů, indukovala zástavu buněčného cyklu v G2/M fázi a vyvolala sérii 
změn v buněčné morfologii. Přítomnost dalších specifických změn (tzn. vznik 
obrovských mnohojaderných buněk, zvýšená exprese p21 a aktivace kaspázy-2) 
naznačila mitotickou katastrofu, po které následovala na k spáze-3/7 závislá 
apoptotická buněčná smrt. Další analýzy prokázaly, že oba procesy nespojuje 
aktivovaná signální dráha TP53-BAX, a jejich podrobnější mechanizmy budou tedy 
předmětem budoucích studií. 
Protinádorová aktivita FLU byla také ověřována u melanomových buněk 
odvozených z explantátových kultur získaných ze vzorků melanomu od pacientů 
léčených ve Fakultní nemocnici Hradec Králové. V pilotní studii prováděné na buňkách 
vzorku od vybraného pacienta FLU vyvolal inhibici růstu a cytotoxicitu, nicméně buňky 
na něj vykazovaly nižší citlivost (dle získané hodnoty IC50). Dále testovaná koncentrace 
FLU 1 µM vykazovala cytostatický účinek a vyvolávala velmi ojedinělé morfologické 
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změny u exponovaných buněk, významně odlišné od dříve pozorované mitotické 




3. USED ABBREVIATIONS 
 
ABC  ATP binding cassette 
AIF  apoptosis inducing factor 
ALM  acral lentiginous melanoma 
APAF1  apoptotic protease activating factor 1 
ATG4B  autophagy-related protein 4B 
BAX  BCL2-associated X protein 
BCA  bicinchoninic acid 
BRAF  v-Raf murine sarcoma viral oncogene homolog B 
BSA  bovine serum albumin 
CDK4  cyclin-dependent kinase 4 
CDKN1A  cyclin-dependent kinase inhibitor 1A 
CDKN2A  cyclin-dependent kinase inhibitor 2A 
CHAPS  3-[(3-cholamidopropyl)dimethylam-monio]-1- 
            propanesulfonate hydrate 
c-MYC  Myc proto-oncogene protein 
CTLA-4 anti-cytotoxic T-lymphocyte antigen 4 
DAPI  4',6-diamidino-2-phenylindole 
DMEM  Dulbecco’s modified Eagle medium 
DMSO  dimethylsulfoxide 
DOPA  dihydroxyphenylalanine 
DTIC dacarbazine 
DTT  dithiotreitol 
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EDTA  ethylenediaminetetraacetic acid 
EdU  5-ethynyl-2′-deoxyuridine 
EMEM  Eagle’s minimal essential medium 
EMT  epithelial-to-mesenchymal transition 
FBS  fetal bovine serum 
FLU  flubendazole 
GNA11  G Protein Subunit Alpha 11 
GNAQ  guanine nucleotide-binding protein G(q) subunit alpha 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IFN- α interferon- α 
IL-2 interleukin-2 
LM  lentigo melanoma 
MAPK  mitogen activated protein kinase 
MART-1  melanoma-associated antigen recognized by Tcells-1 
MC1R melanocortin 1 receptor 
MDR  multi-drug resistance 
MITF microphthalmia-associated transcription factor 
NM  nodular melanoma 
NRAS  neuroblastoma RAS Viral Oncogene Homolog 
PBS  phosphate-buffered saline 
PI3K phosphatidylinositol-3-kinise 
PKC  protein kinase C 
POMC proopiomelanocortin  
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PTEN  phosphatase and tensin homolog 
ROS  reactive oxygen species 
RPM  revolutions per minute 
RT   room temperature 
SSM  superficial spreading melanoma 
TP53  tumor protein p53 
TRP1  tyrosinase-related protein 1 
TRP2  tyrosinase-related protein 2 
TYR  tyrosinase 
WNT  Wingless-related integration site 
WST 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-
benzene disulphonate 
XIAP  X-linked inhibitor of apoptosis 
 
α-MSH  α-melanocyte-stimulating hormone
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4. THEORETICAL PART 
4.1. Malignant melanoma 
4.1.1. Definition 
Melanoma is a malignant tumor arising from melanocytic cells and primarily 
involves the skin. The neuroectodermal origin of melanocytes explains the occurrence 
of tumors in other tissues too. In fact, melanomas c n also arise in the eye (uvea, 
conjunctiva and ciliary body), meninges and on various mucosal surfaces but their 
occurrence is rare. Melanomas are usually heavily pigmented but they can be also 
amelanotic. Melanoma is characterized by aggressive growth and even small tumors 
may have a tendency to metastasize (1). 
   
4.1.2. Epidemiology 
The incidence of cutaneous malignant melanoma is increasing worldwide in white 
populations, in particular in regions with excessive sun exposure of fair-skinned 
individuals (Figure 1). 
People with light complexions, an inability to tan, blond or red hair, or blue eyes 
have a higher risk of melanoma than the general population. The highest incidence rates 
have been reported from Australia with 56 new cases per year per 100,000 for men and 




Figure 1 - Incidence of melanoma of skin in the Czech Republic and other world countries (www.svod.cz, adapted) 
 
During the past 30 years, the incidence of melanoma f skin in the Czech Republic 
increased almost 5 times with reported 25.9 new cases per 100,000 inhabitants in 2012 
(4,5; Figure 2).  
 
Figure 2 - Incidence of melanoma of skin in the Czech Republic (www.svod.cz, adapted) 
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Genetic factors play a dominant role in risk for melanoma. In addition to skin 
pigmentation, other heritable risk factors include family history of melanoma, density 
and type of existing nevi, and propensity to sunbur but not tan (6). Inherited mutations 
in the CDKN2A and CDK4 genes encoding the tumor-suppressor proteins p16 and p19, 
which have been documented in some families with hereditary melanoma, confer a 60 
to 90 % lifetime risk of melanoma (7, 8). 
It is widely accepted that a person's total risk of melanoma is determined through 
the interplay between genetic factors and environmental factors, in particular exposure 
to sunlight (3). The effects of solar radiation in melanoma development are nevertheless 
not clear. The existing evidence seems to implicate the activity of the mutagenic UV-B 
radiation (i.e. the one responsible for sunburn and tanning) as well as the 
proinflammatory, melanocyte activating effects of UV-A wavelengths (i.e. the one 
responsible for tanning). In addition, UV radiation has immuno-suppressive effects in 
the skin, thereby at least theoretically interfering with immunological mechanisms of 
cancer surveillance. Perhaps the clearest evidence for the tight relationship between UV 
exposure and the risk of melanoma development comes from a rare genetic disorder 
called xeroderma pigmentosum. Xeroderma pigmentosum is an autosomal recessive 
heritable condition characterized by molecular defects in the nucleotide excision repair 
of UV-B-induced DNA damage. Patients with xeroderma pigmentosum develop large 
numbers of non-melanoma skin cancers by early adulthood, and a subset of them are at 
high risk for melanoma development (6). 
 
4.1.3. Different subtypes of melanoma 
There are four different subtypes of melanoma which are distinguished by clinical 
and histopathological features with distinct epidemiological parameters and particular 
patterns of mutation (1; Figure 3).  
• Superficial spreading melanoma (SSM) - is the most common form of 
melanoma. It usually occurs in middle age but may appe r in younger people 
too. In most cases it is flat with an intra-epidermal component and often with 
multiple colors and pale areas of regression. 
• Nodular melanoma (NM) - most often occurs in middle age and is more 
frequent in males.  It is an exophytic brown-black, often eroded or bleeding 
tumor, which consists of raised nodules. Nodular melanoma is characterized 
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by an aggressive vertical phase, with a short or absent horizontal growth 
phase. Due to this growth dynamics, its early identifica ion in an 
intraepidermal stage is almost impossible. 
• Lentigo maligna melanoma (LM) - usually occurs in older generation, most 
commonly on the face. It’s usually flat in appearance, with dark brown or 
black color and is associated with lifetime chronic sun exposure. 
• Acral lentiginous melanoma (ALM) - is most frequent type of this 
malignancy in non-Caucasian populations (e.g. Asians d Africans). It 
usually occurs on the palms of the hands, the soles of the feet and in the nail 
bed. The occurrence of this melanoma type is thus not associated with UV 
exposure (1, 9, 10). 
 
 
Figure 3 - Different subtypes of melanoma. 1 - Superficial spreading melanoma, 2 - Acral lentigi ous melanoma, 3 - Lentigo 
maligna melanoma, 4 - Nodular melanoma. (http://courses.washington.edu/hubio567/melanoma/types.htm, adapted) 
 
4.1.4. Diagnosis and staging 
The large majority of persons diagnosed with melanoma are cured (> 85 %) due to 
the diagnosis at early stages of tumor development. O  the other hand, melanoma can 
be highly malignant, because it is known to early metastasize to almost any organ in the 
body. Consequently, melanoma diagnosis at later stage  of tumor progression is 
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associated with a poor prognosis. To assist physicians in early recognition of melanoma 
the ABCDE rule has been established: 
• A = asymmetrical shape (melanoma lesions are often irregular or not 
symmetrical in shape)  
• B = border irregularity 
• C = color (the presence of more than one color can be a warning sign of 
melanoma)  
• D = diameter (melanoma lesions are often greater than 6 millimetres in 
diameter) 
• E = evolution (6,11) 
 
Clinically, melanoma is classified into four stages r ferred to as TNM classification 
(12). This classification describes the size and extent of the primary tumor - T (tumor), 
presence and extent of metastases in regional lymph nodes - N (nodule) and whether the 
melanoma has metastasized to distant organs- M  (metastases) (13). 
According to histopathological stages, melanoma is also divided into 5 groups 
(0-IV). In situ melanomas (stage 0) are noninvasive without disturbed integrity of the 
epidermal basement membrane. Stage I and stage II mlanomas are localized primary 
tumors without any regional or distant metastases. Stage III melanoma is characterized 
by regional spread through lymphatic vessels and in stage IV melanoma distant 
metastases are disseminated through hematogenous spread (6). 
In addition to the TNM classification, there is a Breslow histological evaluation 
where the depth of melanoma invasion into epidermis in millimetres is rated (14) or 
Clark's evaluation based on histological changes during the growth and progression of 
melanoma (15). Together with presence of histologically recognized ulceration and 
mitotic rate, Breslow’s depth and Clark’s level belong to the most important histological 
prognosis factors for primary melanoma without metastases (1; Figure 4). 
 
Figure 4 - Depth of invasion determined by Clark’s level and Breslow thickness
Focus on melanoma. Cancer Cell. 2002. Vol.
 
4.2. Melanocytes 
Melanocytes are a heterogen
only in the skin epidermis, hair and eyes. Their major function and characteristics is the 
production of the pigment
 
4.2.1. Evolution of melanocytes
Melanocytes differentiate from melanoblasts with
migrate to stratum basale of 
follicles or to the uveal tract of the eye and the retina
melanocytes is regulated by epidermal keratinoc
Melanocytes are oval, dendritic cells, smaller than keratinocytes. We can 
in the basal layer of epidermis
form the epidermal melanin units
to keratinocytes is about 1:10 and this ratio
the epidermal melanin unit, the expression of the sp cialized adhesion
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 (Houghton, Alan N. and Polsky, David, 2002. 
 2, no. 4, p. 277) 
eous group of pigmented cells occurring 
 melanin responsible for skin and hair colour 
 
in the neural crest and then begin to 
the epidermis. Alternative pathways also lead them to hair 
 (16). The homeostasis of 
ytes (17). 
 where they, together with 30-40 associated keratinocytes
. In the epidermal basal layer the rati
 s maintained throughout the human life
 




o of melanocytes 
. In 
 molecules such 
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as E- and P-cadherins demonstrates the existence of lose cell-to cell contacts. These 
contacts between the dendritic processes of differentiat d melanocytes and 
keratinocytes are necessary for the melanin transfer into keratinocytes, which 
determines the skin color and confers photoprotection (18). 
 
4.2.2. Melanogenesis 
Synthesis of melanin is a biochemical process called m lanogenesis. It takes place 
in melanocytes, in separate cytoplasmatic organelles called melanosomes (18). 
Melanosomes are large, lysosome-related organelles. They synthesize two kinds of 
melanin pigments: eumelanin and pheomelanin. Eumelanin is brown-black or dark 
insoluble polymer, which is found in dark skin and black hair, and pheomelanin is red-
yellow soluble polymer connected to the red hair and freckled skin type. Both types of 
melanin show a different way of synthesis (19, 20). 
Melanogenesis is a complex process involving three enzymes: tyrosinase (TYR), 
tyrosinase-related protein-1 (TRP-1) and tyrosinase-related protein-2 (TRP-2 - 
otherwise known as dopachrome tautomerase, DCT), with TYR being absolutely 
necessary for melanogenesis. 
The synthesis of melanin is initiated with hydroxylation of tyrosine to 
L-3,4-dihydroxyphenylalanine (DOPA) and catalyzed by the enzyme TYR (Figure 5). 
DOPA is then rapidly oxidized to DOPAquinone in the pr sence of TYR again. These 
two steps are common for both eu- and pheomelanogenesis pathways (18, 19).  
Eumelanogenesis involves further transformation of DOPAquinone to DOPAchrome. 
The DOPAchrome spontaneously loses carboxylic acid with the production of the 
intermediates dihydroxyindole (DHI) and DHI-2-carboxylic acid (DHICA) in case the 
DCT enzyme is present. DHI and DHICA then undergo polymerization to form 
eumelanin. Pheomelanogenesis also starts with DOPAquinone, which reacts with 
cystein to yield cysteinylDOPA. CysteinylDOPA then oxidizes and polymerizes to be 




Figure 5 - Scheme of melanin synthesis during melanogenesis in melanocytes 
biology and development. Advances in Dermatology and Allergology
 
 
Human skin normally contains a mixture of all types
part determines visible pigmentation 
individuals from different
individuals with different pigmentary phenotypes and
fact, it is the ratio of eumelanin to total me
pheomelanin content does not 
Moreover, eumelanin is superior to pheomelanin in




(Cichorek M. et al.
. 2013. Vol. 30, no. 1, p. 34, adapted
 of melanins
(21). The diversity of skin pigmentation among 
 ethnic groups is preserved in melanocytes cultured f om 
 depends on eumelanin content
lanin which decides about skin color 
appear to consistently correlate with skin pigmentation. 
 its photoprotective properties
, 2013. Skin melanocytes: 
) 
 and their ratio in 
. In 
whereas 
 due to 
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4.2.3. Regulation of melanogenesis 
The synthesis of melanin is stimulated mainly by UVirradiation, which generates 
DNA photoproducts and leads to the release of various autocrine and paracrine factors. 
The most important factor secreted by keratinocytes is α-melanocyte-stimulating 
hormone (α-MSH). α-MSH is derived from its precursor proopiomelanocortin (POMC). 
The plasma membrane of skin melanocytes contains the melanocortin 1 receptor 
(MC1R) which is activated by α-MSH. This activation of MC1R receptor leads to 
stimulation of the expression of microphthalmia-associated transcription factor (MITF), 
which is essential for normal synthesis of melanin i  melanocytes. The activity of MITF 
contributes to the expression of a host of genes that are involved in melanocyte survival, 
motility, differentiation, apoptosis and in melanosome production of tyrosinases (20). 
 
4.2.4. Melanocyte biology and transformation 
The number, organization and biological activity of melanocytes in the epidermis 
are controlled and regulated by several genetic, epigenetic and environmental 
mechanisms whose interactions and full elucidation are still elusive. Melanocytes are 
highly differentiated cells characterized by a long life-span, increased resistance to 
environmental stresses and low proliferative activity. All aspects of this status are 
maintained via a complex interplay of diverse growth factors, paracrine factors and/or 
expression of cell surface molecules mediated by the interactions between melanocytes, 
keratinocytes, fibroblasts or other organs (e.g. pituitary gland) (18). Furthermore, these 
“internal” players are under the influence of environmental factors, in particular UV 
radiation. UV radiation “activates” keratinocytes which secrete a series of factors to 
enhance melanocyte proliferation thought to be respon ible for the formation of nevi. 
The melanocytes in a nevus do not significantly morph logically differ from normal 
melanocytes; however, they may start expressing growth factors and often harbor some 
genetic changes typical of fully developed melanoma (23). Nevus cells stop 
proliferating at a certain stage to create a pigment c lls population forming a mole (24). 
This proliferation arrest is seemingly under the contr l of the cell cycle inhibitor 
p16INK4A as the defects in CDNK2A expression correlate with an increased number of 
moles and a higher risk of mole transformation (25). Many moles/nevi never progress to 
further malignant stages to become melanoma and if so, this progress seems to be 
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highly individual with a gradual accumulation of genetic and epigenetic changes and 
a strong influence of microenvironment over linear or non-linear fashion (23). 
 
4.3. Genomic landscape of melanoma 
According to The cancer genome atlas data, the mutation rate of melanoma is 
amongst the highest of all analysed malignancies (26). The detailed enumeration of 
genetic and epigenetic changes detected in various forms of melanoma is beyond the 
scope of this introduction; however, some most commnly found genetic alterations are 
summarized in Figure 6. 
Gene Gene type Alteration frequency/type(s) in melanoma 
BRAF Protooncogene Mutation (50-70 %) 
NRAS Protooncogene Mutation (10-30 %) 
AKT3 Protooncogene Overexpression 
NF1 Tumor suppressor Mutation (12-18 %)* 
KIT Protooncogene Mutation (3 %), amplifications**  
GNAQ G protein Mutation (1-2 %)**  
GNA 11 G protein Mutation (1-2 %)**  
CDKNA2A Tumor suppressor gene Deletion, mutation or silencing (30-70 %) 
PTEN Tumor suppressor gene Deletion or mutation (5-20 %) 
APAF1 Tumor suppressor gene Silencing (40 %) 
Cyclin D1 Protooncogene (putative) Amplification (6-44 %) 
MITF Transcription factor Amplification (10-16 %) 
 
Figure 6 - Selected genetic alterations in malignant melanoma (Gray-Schopfer et al., 2007. Melanoma biology and new targeted 
therapy. Nature. 22 2007. Vol. 445, no. 7130, p. 853. * Kiuru et al., 2017. The NF1 gene in tumor syndromes and melanom . 
Laboratory investigation; a journal of technical methods and pathology. 2017. Vol. 97, no. 2, p. 146–157. ** Lyle et al., 2013. 
Diagnosis and treatment of KIT-mutant metastatic melanoma. Journal of Clinical Oncology. 2013. Vol. 31, no. 26, p. 3176–3181, 
adapted) 
 
With increasing technical possibilities of genetic and epigenetic analysis (e.g. next 
generation sequencing), more detailed cataloguing of individual driver (signature) 
genetic changes is possible which has recently led to the proposed molecular 
classification of cutaneous melanoma into four genomic subtypes designated as BRAF, 
RAS (N/H/K), NF1, and Triple-WT (27). This proposed scheme endeavors to take into 
consideration not only general melanoma as such but also defined melanoma subtypes 
characterized by particular mutations: superficial spreading melanoma (SSM) and 
nodular melanoma (NM) which associate with BRAF or NRAS mutations; acral 
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lentiginous melanoma (ALM), lentigo maligna (LM), and mucosal melanoma that are 
more often positive for KIT mutations; and ocular melanomas often positive for GNAQ 
or GNA11 alterations (28). In addition, while individual genetic and epigenetic changes 
are extensively mapped and characterized, little is known about their succession and 
sequential order in melanoma evolution. To this end some recently published data 
formulate our first efforts to link melanomagenesis with the time frame of underlying 
molecular changes (29, 30; Figure 7). 
 
 
Figure 7 - Proposed models of sequential melanoma progression integrating molecular, evolutionary and histopathological 
data. (Shain, et al. 2015. The Genetic Evolution of Melanoma from Precursor Lesions. New England Journal of Medicine. 2015. 




While some altered genes or genomic segments in concerned melanocytes often 
control generally known signaling pathways, others have a separate or unclear status 
and their involvement in particular signaling networks needs to be further specified. In 
the past, several key molecular pathways have been identified that are involved in 
melanoma onset, progression, and metastatic spread. Some crucial examples of these 




Figure 8 - Proposed sequential epigenetic changes in melanoma development. 
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MEK-ERK signaling and lead to enhanced proliferation, survival, invasion and 
angiogenesis of melanoma (9, 33). 
 
4.3.2. PI3K/AKT pathway 
The phosphatidylinositol-3-kinase (PI3K) pathway isnvolved in various 
physiological functions within the cell including cell growth, proliferation and 
metabolism. PI3K is known to occur in three classes, with the class 1 being the most 
characterized. Following its activation, this kinase catalyzes the production of a series 
of phospholipid derivatives functioning as second messengers to ultimately 
phosphorylate serine/threonine kinase AKT. AKT in turn is known to phosphorylate up 
to 100 target proteins and via various regulatory mechanisms elicits strong survival 
effects in the concerned cells. Upon physiological circumstances, this signalization is 
negatively regulated by PTEN (phosphatase and tensin homolog deleted on 
chromosome 10) induced dephosphorylation of second messengers resulting in reduced 
AKT levels and inhibition of P3IK signaling pathway. 
Numerous studies have shown that PI3K/AKT pathway pl s a rather important role 
in biology of melanoma and its therapeutic resistance. Uncontrolled activity of 
PI3K/AKT signaling is linked with PTEN loss/inactivation occurring in 10-30 % of 
melanoma and increased expression of AKT3 by gene amplification is found in about 
60 % of sporadic melanomas (23, 25, 26). NRAS and PTEN mutations were first 
reported to be mutually exclusive in melanoma, which is likely explained by their 
ability to share the same signaling pathway. However, recent data indicate that PI3K 
pathway mutations occur together with mutant NRAS in 9 % of tumors. Cooperation of 
BRAF and PTEN mutations was reported in 17 % of melanomas (27). 
 
4.3.3. WNT signalling 
WNT (Wingless-related integration site) signaling controls several processes 
important in embryogenesis (cell fate, polarity) as well as in adulthood (proliferation, 
migration). WNT family glycoproteins bind to the extracellular receptor (seven 
transmembrane Frizzled – FZD) proteins to start three possible signaling pathways: a 
canonical β-catenin-dependent pathway, a non-canonical β-catenin-independent 
pathway and a WNT-dependent, protein kinase C (PKC)-dependent pathway. WNT 
signaling is crucial for the development of melanocytes from their neural crest 
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precursors and abnormal activation of the WNT pathwy has been shown to play a key 
role in development of melanoma although details remain as yet unclear (32). One 
known link might a gene Microphthalmia-associated transcription factor (MITF) 
encoding a transcription factor promoting survival in melanoblasts and driving 
melanocyte lineage commitment. MITF regulates the expression of melanogenic 
proteins such as tyrosinase, silver homologue (GP100) and melanoma-associated 
antigen recognized by T cells-1 (MART-1) and since it is expressed in most human 
melanomas its target genes are a di gnostic marker for this malignancy. Furthermore, 
stable, unrepressed MITF expression is essential for melanoma cell proliferation and 
survival (9). 
Recent studies have shown that oncogenic BRAF may control intracellular levels of 
the MITF protein through a fine balance of two opposite mechanisms: a direct reduction 
of MITF levels, by inducing protein degradation, and an indirect increase of MITF 
levels, by stimulating transcription factors which increase protein expression levels. It 
has been shown that oncogenic BRAF mutations are associated with MITF amplification 
in a low fraction (10-15 %) of melanomas, suggesting hat other mechanisms are likely 
to be involved in ERK-dependent degradation of MITF (24). 
 
4.3.4. CDKN2/CDK4 tumor suppressive pathway 
The CDKN2A is another major gene involved in melanoma pathogenesis and 
predisposition. It encodes two proteins, p16 and p14, both known as tumor suppressors. 
Proteins p16 and p14 are known as inhibitors of the cell cycle, which negatively 
interfere with the activity of the cyclin/CDK complexes and, in this way, ensure the 
control of the cell replication. The inactivation of CDKN2A is mostly due to point 
mutations (about 10 % of cases), genomic deletions (approximately 50 % of cases), or 
silencing. These mutations lead to the loss of the m chanisms controlling cell 
proliferation and / or survival (33, 37). 
 
4.3.5. p53 pathway 
 p53 regulates positively or negatively many genes involved in cell cycle regulation 
(CDKN1A), induction of autophagy, senescence, and apoptosis (NOXA, PUMA, and 
BAX), as well as genes involved in the DNA repair or cellular metabolism. Mutations of 
p53 are found in approximately 50 % of human cancers, but only sporadically and lately 
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in melanoma (about 10 % of cases). Why frequency of p53 mutations is the lowest in 
melanomas compared to other malignancies remains to be solved (33, 36). Although 
direct mutations in p53 are infrequent in melanoma, inactivation of TP53 pathway 
occurs more via CDKN2A and loss-of-function of its product p14ARF (33). 
 
4.4. Chemoresistance 
Chemoresistance or drug resistance of malignant cells is established as the primary 
cause of failure of chemotherapeutic treatment of mst human tumors. Traditionally, 
chemoresistance is classified as intrinsic or acquired on the basis of the initial response 
to the first therapy with several pharmacological (e.g. tumor drug delivery, drug 
metabolism and selectivity etc.) as well as cellular (e.g. enhanced expression of drug 
efflux proteins, alterations in drug-targets, increas d tolerance to stress conditions, and 
suppressed cell death signaling) mechanisms. 
 
4.4.1. Chemoresistance in melanoma 
Melanoma is an aggressive and multi chemoresistant type of malignancy with many 
of the above-mentioned drug-resistance mechanisms pre ent inherently. Due to 
melanoma recognized intratumor heterogeneity, their presence is further linked with 
other transformation relevant features such as the epithelial-to-mesenchymal (EMT) 
transition and cancer cell stemness. Thus malignant melanocytes may develop a multi-
drug resistance (MDR) phenotype related to overexpression of ATP-binding cassette 
(ABC) transporters, in particular ABCB5 (29) responsible for an efflux of a wide range 
of chemotherapeutics (38). Conversely, the involvement of drug target alterations as 
well as the expression of detoxification enzymes in chemoresistance of melanoma 
continues to be controversial.  
Given their natural role in superficial layers of our body, normal melanocytes are 
also endowed with enhanced survival mechanisms. These include for example increased 
expression of BCL-XL and MCL-1 antiapoptotic proteins which are also strongly 
expressed in all stages of melanomagenesis, thereby possibly contributing to melanoma 
resistance. In fact, based on the current evidence melanoma cells considerably rewire 




Other processes such as autophagy and its aberrant regulation play roles in 
melanoma survival too via so called autophagy paradox. This implies loss or 
deregulation of tumor suppressive autophagy in early stage malignancy and its 
upregulation in more advanced stages by helping melanoma cells escape drug-related 
toxicities (39). 
 
4.5. Treatment of malignant melanoma 
4.5.1. Surgical therapy 
The primary treatment of melanoma is surgical excision (3), in particular wide 
excision, with either 1-2 cm margin of grossly normal tissue down to, but not including 
muscular fascia (28). In patients with high-risk factors such as tumor thickness (depth 
greater than 4 mm), ulceration, high mitotic rate or regional node involvement, the risk 
of developing metastases can be very high (30-80 %) so systemic therapy is needed 
(33). 
 
4.5.2. Radiation therapy 
Radiation therapy of the primary tumor is very rarely indicated; it is performed 
exclusively in patients in whom surgery is impossible or not reasonable (3). This 
therapeutic approach is used for an uncommon type of melanoma known 
as desmoplastic melanoma or it can be used in combination with surgical therapy. 
Sometimes, radiation is given after surgery in the ar a where lymph nodes were 
removed or is used to relieve painful bone and brain metastasis. Treatment with the goal 
of relieving symptoms is called palliative therapy. Palliative radiation therapy is not 
expected to cure the cancer, but it might help shrink it or slow its growth for a time to 
help control some of the symptoms (40). 
 
4.5.3. Immunotherapy 
It is mainly used as an adjuvant treatment for patients with primary melanoma stage 
II and III (41). In immunotherapy two main molecules are used: interleukin-2 (IL-2) for 
advanced melanoma and the interferon alpha (IFNα) which is employed alone after 
surgery or in combination with other agents in advanced melanoma. However, treatment 
of melanoma patients with both immune system activating molecules failed to deliver 
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any clinically meaningful objective response rate and did not result in any improvement 
in overall survival as based on clinical trial evidence (42). 
 
4.5.4. Systemic therapy 
The major indications for systemic therapy are inoperable regional and distant 
melanoma metastases (stage IV). Beside the standard cytostatic drugs, which were 
capable of inducing tumor responses but not of prolonging survival, new targeted 
compounds have been shown to prolong patient survival. The two main goals of 
systemic therapy are prolongation of survival and reduction of tumor size (3). 
 
4.5.4.1. Chemotherapy 
Currently, no compound is known that would clearly improve patient prognosis. 
A number of agents with comparable effectiveness are vailable for systemic 
chemotherapy of advanced melanoma. The longest-established monotherapy is based on 
dacarbazine (DTIC) (3). Treatment with DTIC alone or in combination has re ulted in 
low response rates (about 10-20 %), rare durable responses with no impact on survival 
(33). Temozolomide, an oral prodrug that yields the same active intermediate as 
dacarbazine, has been demonstrated to be as effective as DTIC, although more 
expensive. The antitumor activity of combinations of chemotherapeutic agents 
including cisplatin, vinblastine, dacarbazine and tamoxifen have failed to demonstrate 
a survival benefit compared with dacarbazine alone t o (41). 
The combination of chemotherapy with immunotherapy resulted in increased 
response rates, however, survival benefit has not been demonstrated while toxicity was 
significantly increased (33). 
 
4.5.4.2. Targeted therapy 
The increased knowledge about the molecular pathogenesis of melanoma has helped 
the research in the melanoma treatment. New agents used in melanoma treatment are 
the highly selective BRAF inhibitors (vemurafenib, dabrafenib), highly specific 
inhibitor of MEK (trametinib) or monoclonal antibody of anti-cytotoxic T-lymphocyte 
antigen 4, CTLA-4, (ipilimumab) (33). 
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Furthermore, in 2015 talimogene laherparepvec (T-VEC, also known as 
OncoVEXGM-CSF) became the first oncolytic virus approved for therapy in melanoma 
patients with injectable but non-resectable lesions in the skin and lymph nodes in the 
USA (43). 
 
Overall, targeted therapies have been clinically impactful for melanoma 
management, although they suffer from the drawback of resistance development after 
initial response or a lack of translation of target inhibition into disease control. The 
future of targeted therapies in melanoma management rests on successful translation of 
the understanding of the biological mechanisms of resistance into clinically significant 
therapeutic combinations (44). 
 
4.5.5. Novel approaches 
Due to our constantly improving knowledge about molecu ar changes and 
corresponding biology of malignant tumors, novel pharmacological targets and 
approaches in oncological therapy are identified antested. One such an approach is 
known as drug repurposing (repositioning); i.e. finding new indications of existing 
drugs (45). This strategy holds a promising potential and to the date, in fact there are at 
least 46 approved drugs already repositioned for new therapeutic uses as indicated in 
literature (46, 47). One example candidate chemical group for repurposing is 
benzimidazole derivatives.  
 
4.6. Benzimidazole derivates 
Benzimidazoles are the fused heterocyclic ring structures, which form an integral 
part of vitamin B12. Substitution of benzimidazole nucleus has been shown to modify 
chemical and pharmacological properties of the structu e and was a crucial step in the 
drug discovery process. The first benzimidazole to be developed and licensed for human 
use was thiabendazole in 1962 followed by a number of veterinary anthelminthics 
(parbendazole, fenbendazole, oxfendazole and cambendazole). The first benzimidazole 
carbamate used in humans was mebendazole, followed by flubendazole. Currently, 
some derivatives of benzimidazole are clinically approved including albendazole, 
mebendazole, thiabendazole as anthelmintics; omeprazole, lansoprazole, pantoprazole 
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as proton pump inhibitors; astemizole as antihistaminic; enviradine as antiviral; 
candesarten cilexitil and telmisartan as antihypertensives (48). 
 
4.6.1. Mechanism of action of benzimidazole carbamates  
Benzimidazole carbamates specifically bind and interact with the β-tubulin subunit 
of microtubules (49), despite the fact that their affinity for a mammalian tubulin is 
weaker than in helminths (50). Since microtubule structures are very important for 
many vital functions of the parasite such as proliferation, mitosis, intracellular transport 
of organelles, maintenance of cell shape or cell locomotion, alteration of microtubular 
assembly and dynamics leads to the final destruction of the parasite (49, 51, 52). In 
addition, benzimidazole carbamates may also inhibit energy metabolism of parasite 
cells. They cause disruption of transport and metabolism of glucose, resulting in energy 
and glycogen store depletion and loss of cellular motility. Even this process ultimately 
contributes to the death of the parasite (53, 54). 
 
4.6.2. Anticancer properties of benzimidazole carbamates  
Benzimidazole carbamates interact with microtubules in helminths and were shown 
to bind with mammalian tubulin in vitro. This raised the question of whether this class 
of compounds could inhibit tubulin polymerization in human cells too and if so whether 
such a targeted effect could lead in a wider context to their antiproliferative and/ or 
antitumor effects in humans. First study to address this issue was published as early as 
in 1985. Still, more thorough inquiry into antiproliferative potential of benzimidazole 
carbamates was realized much more later. In a series of published studies, albendazole 
and mebendazole proved to be cytotoxic and cell death inducing compounds in a wide 
range of tumor cells as well as xenographt models (46).
 
4.6.3. Flubendazole 
Flubendazole (FLU) is a synthetic anthelmintic compund (Fig. 9), which was 
found by Janssen company in 1970s. In Europe, FLU is registered also for human use 





Figure 9 - Structure of flubendazole (FLU) 
 
4.6.4. Anticancer effect of FLU 
Anticancer activity of FLU was first reported in leukemia and myeloma cell lines 
where FLU inhibited cell growth and proliferation, arrested cell cycle and induced 
mitotic catastrophe. Similar effects were also observed in breast cancer cell lines MDA-
MB-231, BT-549, MCF-7 and SK-BR-3 cells where in addition to classical inhibitory 
effects FLU induced cell differentiation and inhibited cell migration, which was 
accompanied by reduced expression of mesenchymal markers (β-catenin, N-cadherin 
and Vimentin) and induced expression of epithelial and differentiation marker 
(Keratin 18). In addition, FLU was described to be a potent inducer of reactive oxygen 
species (ROSs) capable of activating autophagy via targeting the autophagy-related 
protein 4B (ATG4B) (46, 55). 
In colorectal cancer cells SW480 and SW 620 FLU inhibited their growth, arrested 
them in G2/M phase and also potentiated the effect of paclitaxel (56, 57).  
Finally, in a screen of a panel of 321 cell lines including cell lines of various cancer 
types, neuroblastoma was identified as another highly FLU-sensitive malignancy type. 
The follow-up experiments proved that FLU displayed broad activity towards primary 
neuroblastoma cells obtained from five patients and  panel of 140 neuroblastoma cell 
lines with acquired drug resistance against major mic otubule-binding compounds. The 
specific activity of FLU aimed p53-signalling and namely the protein PUMA which was 




4.7. Mitotic catastrophe 
In scientific literature, the term mitotic catastrophe is used to describe several 
related but not entirely identical phenomena. In particular, two opposing views are 
currently presented of whether mitotic catastrophe is a mode of cell death or whether it 
represents a series of steps leading to cell death ( ither apoptosis or necrosis) (58). To 
this extent, mitotic catastrophe has been proposed to enote a form of cell death of 
mammalian cells resulting from abnormal mitotic process. In this concept, mitotic 
catastrophe is characterized by several distinct morphological features including the 
formation of large multinucleated cells with deconde sed chromatin, overduplication of 
centrosomes and aberrant mitotic spindles. Moreover, some reports emphasize the 
presence of selected phenotypic features characteristic of apoptosis in cells undergoing 
mitotic catastrophe (59). 
An alternative view of mitotic catastrophe presents it as a sequential process 
culminating in cell death linked with mitosis. In this case, the process itself may be 
triggered by premature or aberrant entry of cells into mitosis due to the presence of 
inducing physical or chemical stressors. These stres ors include DNA damaging agents 
such as doxorubicin or cisplatin, spindle poisons comprising both microtubule 
hyperpolymerizing (eg. taxanes, epothilones or eleutherobins) as well as 
depolymerizing agents (vinca alkaloids, cryptophicins or halichondrins) or inhibitors of 
mitotic proteins (monatrol or hesperidin). Their activities lead to defects in DNA 
(chromosomes) affecting their attachment to mitotic spindle, deranged spindle 
formation associated with defects in checkpoints or multipolar mitosis (60). Based on 
the extent of damage, the length of spindle assembly checkpoint activation and the 
actual cell signaling context, final cell death phenotypes then might be reported 
autophagy, typical caspase-dependent apoptosis, or necrosis (61, 62). 
Despite the fact that cells undergoing mitotic catastrophe may potentially survive it 
and via so called mitotic slippage produce potentially dangerous progeny, in most cases 
mitotic catastrophe leads to cell death. Most malign nt cells (including melanoma) 
show varying levels of genetic instability (63, 64), and it was suggested that further 
stimulation of additional instability might represent a therapeutic strategy. Accordingly, 
malignant cells appear to be more susceptible to cell death following mitotic damage in 
comparison to nontransformed cells (65), thereby making mitotic catastrophe 
a potentially important anticancer strategy which could achieved by a variety of 





In this work we set the following aims: 
1. Determination of biological effects of FLU on normal human melanocytes 
 
2. Investigation of cytotoxicity of FLU in the human malignant melanoma cell lines 
of differing molecular profile A-375, BOWES and RPMI-7951 
 
3. Characterization of mechanisms whereby FLU induces its cytotoxic effects in the 
above mentioned cell lines, in particular with respct to mitotic catastrophe. 
Comparison of these effects with the ones known from other models 
 
4. Obtaining and characterization of melanoma cells from patient samples and 
















6. MATERIALS AND METHODS 




Cell Signaling Technology: 
monoclonal rabbit anti-α-tubulin antibody, rabbit polyclonal anti-Bax antibody, 
polyclonal rabbit anti-p53, polyclonal rabbit anti-phospho-p53 (Ser15) antibody, 
Senescence β-Galactosidase Staining Kit #9860 
DAKO: 
Bcl-2 polyclonal antibody 
Eli Lilly Czech Republic: 
Humulin N 100 IU/ml 
GIBCO: 
penicillin, streptomycin, trypsin/EDTA, Medium 254CF, Human Melanocyte Growth 
Supplement (HMGS), Trypsin Neutralizer Solution 
Invitrogen-Molecular Probes: 
Click-iT® EdU Flow Cytometry Assay Kit, ProLong® Gold, MitoTracker, 
LysoTracker 
 LGC Standards: 
Eagle’s minimal essential medium (EMEM) 
PAA Laboratories: 
fetal bovine serum (FBS) 
Promega: 
Caspase-Glo® 2 assay, Caspase-Glo® 3/7 assay 
RayBiotech: 
Human/Mouse Phospho-p38 alpha (T180/Y182) ELISA 
Santa Cruz Biotechnology: 
rabbit polyclonal anti-p21 antibody 
Sigma-Aldrich: 
Dulbecco's Modified Eagle's Medium (DMEM), RPMI-1640 medium, 
dimethylsulfoxide (DMSO), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) buffer, 4',6-diamidino-2-phenylindole (DAPI), 
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3[(3-cholamidopropyl)dimethylam-monio]-1-propanesulfonate hydrate (CHAPS), 
bicinchoninic acid (BCA) kit for protein determination, polyclonal mouse anti-β
actin antibody, Triton-X, flubendazole, bovine serum albumin (BSA), 
paraformaldehyde, transferrin 2mg/ml 
Zentiva: 
heparin 25,000 IU/ml 
 
6.2.  Cell lines 
For our experiments we used normal human melanocytes, human malignant 
melanoma cell lines and melanoma cells derived from a patient´s sample obtained from 
Department of Plastic surgery, Faculty teaching hospital in Hradec Králové.  
 
6.2.1. Normal human melanocytes 
• HEM-LP (Fisher Scientific s.r.o. C0025C) human epidermal melanocytes 
are adherent cells isolated from neonatal foreskin from lightly pigmented 
tissue. 
HEM-LP cell line was maintained in Medium 254CF, with added calcium chloride 
and Human Melanocyte Growth Supplement (HMGS), upon standard conditions 
(37 °C, 5% CO2 in an incubator). The cells were passaged once a wek using 0.05% 
EDTA/trypsin and the Trypsin neutralizer solution was added once the most of the cells 
were nearly completely round. The cells with Trypsin neutralizer solution were then 
transferred to a conical tube and centrifuged at 500 rpm for 5 minutes. The pellet was 
then resuspended with a fresh Medium 254 and 1/5 of suspension returned to the 
cultivation flask. The medium was changed every 2-3 days. Only mycoplasma-free cells 




6.2.2. Human malignant melanoma cell lines 
We were using three different melanoma cell lines: 
• A-375 (ATCC® CRL1619™) are adherent, epithelial cells hypotriploid with 
a modal number of 62 chromosomes whose BRAF and CDKN2A genes are 
mutated. 
• BOWES (ATCC® CRL9607™) are adherent, epithelial, heteroploid cells 
with wild-type BRAF. 
• RPMI-7951 (ATCC® HTB66™) are adherent, epithelial-like cells derived 
from metastasis to the lymph node, hyperdiploid (47-66 chromosomes) with 
mutant BRAF, p53, CDKN2A and PTEN. 
A-375 and BOWES were maintained in DMEM medium supplemented with 10 % 
FBS and 1 % penicillin/streptomycin. RPMI-7951 was cultivated in EMEM medium 
with 10 % FBS and 1 % penicillin/streptomycin. Cells were maintained under standard 
laboratory conditions (37 °C, 5% CO2) in an incubator and passaged twice a week upon 
reaching 90% confluence using 0.05 % EDTA/trypsin. Only mycoplasma-free cells 
were used for experiments. 
 
6.2.3. Human explant melanoma cultures isolated from patients 
Human dermal melanocytes were obtained from patients u dergoing skin surgery at 
the Faculty teaching hospital in Hradec Králové. The study was approved by local 
ethics committee and in all cases tissues were obtained from subjects upon their 
informed consent. 
Samples of a tumor tissue obtained by surgery were transported in a 50 ml tube with 
transport medium (RPMI-1640, 15 % foetal bovine serum, humulin N 100 IU/ml, 
transferrin, heparin) at room temperature to the Department of Medical biology and 
genetics where they were further processed. The tissue in the transport medium was 
placed on a Petri dish and cut into small pieces using cissors and ascalpel. Small 
pieces of the tissue were then collected with a Pasteur pipette and transported into 
cultivation flasks with cultivation medium (RPMI-1640, 1 % penicillin/streptomycin, 
15 % FBS, humulin N 100 IU/ml, transferrin 2mg/ml). Samples were maintained upon 
standard conditions (37 °C, 5% CO2) in an incubator and typically 48 hours post 
isolation individual cells appeared. The fresh medium was then added every 2-3 days 
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until most cells migrated from the tissue fragments and created monolayer on the 
bottom of the flask. 
Cultures were subsequently passaged two times a week using 0.05 % trypsin/EDTA 
upon reaching 90 % confluence and cells were basically characterized.  
During the entire study period, together 5 samples from 5 different patients were 
isolated and cultivated. In none of them detailed cll typing and sorting were carried 
out.  
 
6.3.  Stock solutions of FLU 
Stock solutions of FLU were prepared in DMSO and stored in aliquots at 6 °C. Before 
experiments, FLU aliquots were diluted to the cultivation medium to achieve the following 
concentration range of FLU: 0.01 µM, 0.05 µM, 0.1 µM, 0.5 µM, 1 µM, 5 µM, 10 µM to 
which cell were subsequently exposed. The final concentration of DMSO in the medium 
was 0.1 %. Control samples were treated with a medium containing 0.1 % DMSO. 
 
6.4. Determination of cell viability 
Cell viability assays are based on the determined ratio of living and dead cells in the 
population. To measure cell viability, a number of methods may be used including 
direct microscopy observation and cell counting, determination of membrane integrity, 
measurement of metabolic activity or the rate of DNA synthesis. 
 
6.4.1. The WST assay 
This colorimetric assay is based on cleavage of WST-1 (4-[3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulphonate) by mitochondrial 
dehydrogenases to coloured and insoluble substance - formazan (Figure 10). 
Quantification of the formazan dye produced by metabolically active cells is measured 
with spectrophotometer and absorbance of the cleavage product correlates with the 








Figure 10 - Reduction of WST-1 to formazan (Roche diagnostic 2013, http://www.sigmaaldrich.com/content/dam/sigma-
aldrich/docs/Roche/Bulletin/1/cellprorobul.pdf) 
 
A-375, BOWES and RPMI-7951 melanoma cells were cultured in 96-well plates 
and treated with FLU at a concentration range of 0.01 µM – 10 µM. After 24-, 48- and 
72-hours of exposure, the medium was removed and the cells were washed twice with 
150 µl PBS. Then, 100 µl of culture medium containing WST-1 (0.3 mg/ml) was added 
to each well. Absorbance of the samples was measured immediately at 450nm / 650nm 
wavelength (Tecan Infinite M200; Tecan, Salzburg, Austria). The samples were then 
placed in the incubator and the absorbance was measured again after 2 hours of 
incubation. Each sample was assayed in 6 parallels nd three independent experiments 
were performed. The viabilities of treated cells were xpressed as a percentage of 
untreated controls (100 %). 
Proliferation of HEM-LP cell line was examined at different cell seeding densities 
(100,000 cells/w, 50,000 cells/w, 20,000 cells/w) during different time intervals. WST-1 
assay was performed as described above. 
 
6.4.2. Test of proliferation using xCELLigence system 
The system measures electrical impedance across interdigi ated microelectrodes 
integrated at the bottom of tissue culture E-plates. The impedance measurement 
provides quantitative information about the biological status of the cells, including their 
number, viability and morphology. 
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At the beginning, 90 µl of culture medium were added into each well and plates were 
inserted in the device for background measurement. Then, 100 µl of cell suspension 
(containing 1,500 cells) were added in duplicate to the particular wells. The changes in 
impedance (corresponding to cell proliferation) were measured every 30 minutes for 24 
hours. Next, 10 µl of treatment medium were added into each well, so that the final 
concentration of FLU corresponded to 1 µM. Plates wre inserted back into the device 
and the impedance was measured every hour for total of 72 hours. Each sample was 
assayed in duplicate and three independent experiments were performed. 
 
6.4.3. Microscopy-based cell counting 
HEM-LP cells were cultured in small cultivation flasks and treated with 0.5 µM and 
1 µM FLU. Numbers of living cells were counted with a phase-contrast microscope 
Nikon Eclipse E 400 (Nikon, Prague, Czech Republic) during a 24-96 hours interval. 
Photographs of cultures melanocytes were acquired using software LUCIA DI Image 
Analysis System LIM (Laboratory Imaging Ltd., Prague, Czech Republic), software 
processed and analysed. For the purpose of analysis, the minimum 2,000 cells were 
evaluated at 100x and 400x magnification. A total of six independent experiments were 
performed. 
 
6.5. Time-lapse videomicroscopy 
A-375, BOWES and RPMI-7951 melanoma cell lines as well as HEM-LP cells and 
patient´s melanoma cultivations were individually seeded into plastic tissue-culture 
dishes with glass bottom and left for 24 hours in an incubator with 5% CO2 at 37 °C. Next, 
the growth medium was replaced with a medium containing FLU at a concentration of 
1 µM. The tissue-culture dishes were transferred into a time-lapse imaging system 
BioStation IM (Nikon, Prague, Czech Republic) combining an incubator, a motorized 
microscope and a cooled CCD camera. Recording was carried out in a multipoint and 
multichannel manner employing various time-lapse modes and upon small as well as 
high magnifications to allow global as well as detail d view of changes in behaviour of 
treated cell populations. Recorded sequences were subsequently semi automatically 




6.6.  Cell cycle distribution analysis 
6.6.1.  Flow cytometry 
A-375, BOWES and RPMI-7951 melanoma cells were cultured in 75 cm2 culture 
flasks in 20 ml of culture medium for 12 and 24 hours. Then the culture medium was 
replaced by a fresh medium containing 1 µM of FLU or 0.1 % DMSO as a control. 
After 12 or 24 hours of treatment, the cells were typsinized, collected by 
centrifugation, washed with PBS and fixed with ice-cold 70% ethanol while gently 
vortexing. Fixed samples were stored overnight at 4°C. Next, they were washed with 
PBS and incubated with 0.5 ml of the Vindelov soluti n (1.2 g/l TRIS, 0.6 g/l NyCl, 
0.01 g/l RNase and 0.05 g/l propidium iodide) for 50 minutes at 37 °C. Thus processed 
samples were analysed with the FC500 Cytomics Flow cytometer (Beckman Coulter, 
Hialeah, FL, USA) with PI fluorescence detected in FL3 channel. Cell cycle 
distributions in control and treated samples were analysed with MultiCycle AV for 
Windows (Phoenix Flow Systems, San Diego, USA). Three independent experiments 
were performed. 
 
6.6.2.  Percentage of cells in S-phase by EdU labelling 
EdU (5-ethynyl-2´-deoxyuridine) is incorporated into DNA during active DNA 
synthesis. A-375, BOWES and RPMI-7951 melanoma cells were cultured in 96-well 
plates and treated with FLU at a concentration of 1 µM. After 24 hours exposure, the 
cells were labelled with EdU (Click-iT® EdU Flow Cytometry Assay Kit) at a 
concentration of 10 µM and incubated for 2 hours. After EdU labelling the medium was 
removed and the cells were washed in PBS and fixed with freshly prepared 
paraformaldehyde (4%) and incubated for 15 minutes. After incubation, there were 
washed again with PBS + 3% BSA and permeabilized with 0.5% Triton-X for 
20 minutes at room temperature. After detachment of permeabilization solution, cells 
were washed twice in PBS + 3% BSA and EdU buffer additive was added to the plates 
followed by further incubation (30 minutes in the dark). About 5 minutes before the end 
of incubation DNA-specific solution DAPI (1 µg/ml) was added to the cells. Cells were 
washed again and finally scored using Image Xpress Micro XLS Widefield High-
Content Analysis System. Specific fluorescence was visualized, recorded and analysed 
by Cell scoring module of MetaXpress® Image Acquisition and Analysis Software 
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(Molecular Devices, Sunnyvale, CA, USA). Three independent experiments were 
performed. 
 
6.7. Fluorescent visualisation of mitochondria and lysosomes 
A-375, BOWES and RPMI-7951 melanoma cells were seeded in cytospin chambers 
and allowed to grow overnight at 37 °C. In control ce ls or in cells treated with 1 µM 
FLU, slides with grown cells were rinsed in a warm medium and stained with 
MitoTracker Green FM (100 nM, 30 minutes, 37 °C), LysoTracker Red (30 nM, 
30 minutes, 37 °C) and Hoechst 33528 (10 nM, 30 minutes, 37 °C). Following another 
rinsing with warm cultivation medium, specimens were mounted and mitochondria and 
lysosomes in individual cells were assessed by an epifluorescence motorized 
microscope Nikon Eclipse E 400 (Nikon Corporation, Japan) equipped with a digital 
color matrix camera COOL 1300 (VDS, Vosskűhler, Germany), using a FITC, TRITC 
and DAPI specific filters. Resulting images were analysed by the software LUCIA DI 
Image Analysis System LIM (Laboratory Imaging Ltd., Prague, Czech Republic). All 
experiments were repeated at least three times. 
 
6.8. Caspase assay 
The activities of caspases 2 and 3/7 were assayed using Promega Caspase-Glo 
Assay. A-375, BOWES and RPMI-7951 melanoma cells were cultivated in 96-well 
plates. After 12, 24 and 48 hours incubation of cells in the medium containing 1 µM 
FLU, cells were lysed using buffer containing 50 mM HEPES, 5 mM CHAPS, 5 mM 
DTT. Then the lysates were collected into microtubes. Caspases 2 and 3/7 reagents were 
prepared as described in manufacturer’s instruction. The lysates (25 μl in each well) 
were transferred into white-walled 384-well-plates for luminometer. Then, 25 μl of 
Caspase 2 or Caspase 3/7 reagents were added to each w ll. The plate was gently mixed 
for 30 seconds and then incubated for 30 minutes at room temperature. The 
luminescence was measured in three independent experiments using luminometer 




6.9. Immunofluorescence and image analysis 
A-375, BOWES and RPMI-7951 melanoma cells in cytospine chambers were 
exposed to 1 µM FLU for 12 and 24 hours, then were washed by 1 ml pre-warm PBS 
and fixed with 4% paraformaldehyde (10 minutes, 25 °C), rinsed with phosphate saline 
buffer with 1% Triton X (PBS-T) and blocked in 5% BSA for 1 hour at 25 °C. 
Incubation was performed at 4 °C for 1 hour using α-tubulin (1: 100), ß-actin (1:1,000) 
and p21 (1:100) primary antibodies. After washing with cold PBS (5 minutes, 25 °C), 
secondary antibody (anti-rabbit/anti-mouse, 1:250) was added for additional 1 hour 
(25 °C). The specimens were then rinsed three times n PBS, post-labelled with DAPI 
(10 μg/ml, 15 minutes, 25 °C), mounted into ProLong® Gold medium and examined 
under fluorescence microscope Nikon Eclipse E 400 (Nikon, Prague, Czech Republic) 
(excitation filter 330-380 nm and emission filter 420 nm) equipped with a digital color 
matrix camera COOL 1300 (VDS, Vosskűhler, Germany). Photographs were taken 
using the software NIS Elements AR 3.20. Samples were prepared in duplicates, three 
independent experiments were performed. 
 
6.10. Western blot analysis 
Treated and control cells were washed with PBS and harvested in ice-cold lysis 
buffer (50 mM Tris/HCl, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 
2 mM EGTA, b-glycerolphosphate, 50 mM NaF, 10 mM sodium pyrophosphate, 
200 lM sodium orthovanadate, 2 mM DTT). The lysates were resuspended and 
supernatants were obtained after a 13,000 rpm centrifugation at 4 °C for 10 minutes. 
Amount of protein in supernatant was determined by BCA assay. The SDS sample 
buffer (Tris–HCl pH 6.8, 40% glycerol, 6% SDS, 0.2 M DTT, 0.1 g bromphenol blue) 
and lysis buffer were added according to BCA assay results to obtain the same protein 
concentration of all the samples. Fifteen micrograms of protein were separated on 10 % 
or 15 % (based on protein size) polyacrylamide gels. After electrophoresis (15mA per 
gel, 200V, 75 minutes), proteins were transferred to a PVDF membrane (170 mA, 25V, 
20 minutes for 1 gel) and blocked for 1 hour with 5% nonfat dry milk in TBST (Tris-
buffered saline containing 0.05% Tween 20). Then, the membranes were incubated with 
primary antibody overnight at 4 °C with gentle shaking. These conditions were applied 
for detection of BAX (polyclonal rabbit antibody, 1:1,000), TP53 (polyclonal rabbit 
antibody, 1:1,000) and phospho-TP53 (ser15) (polyclnal rabbit antibody, 1:1,000). 
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In case of β-actin (polyclonal mouse antibody, 1:8,000) and BCL2 (polyclonal mouse 
antibody, 1:400), the incubation with the primary antibody lasted for 1 hour at room 
temperature. Subsequently, the membranes were washed ix times in TBST for 
9 minutes, followed by 1 hour incubation with a secondary antibody at room 
temperature (anti-rabbit secondary antibody, 1:2,000 for BAX, TP53 and phospho-TP53 
(ser15), and anti-mouse secondary antibody 1:800 for BCL2 and 1:10,000 for β-actin). 
After washing the membrane six times (9 minutes) with TBST, the chemiluminescence 
process and quantification of immunoreactive bands on the exposed films were carried 
out using the QuantityOne imaging software (Bio-Rad L boratories, Hercules, CA). For 
each antibody used, three independent experiments were performed. 
 
6.11. Statistics 
Statistical analysis was carried out with a statistical program GraphPad Prism 
(GraphPad Software version 6.0, Inc. San Diego, U.S.A.). We used one-way Anova test 




7.1. Antiproliferative effects of FLU in different melanoma cell lines 
The effect of FLU at a concentration range of 0.01 – 10 µM on viability and 
proliferation of three human melanoma cell lines A-375, BOWES and RPMI-7951 
during up to 72 hours of exposure was evaluated with formazan assay WST-1. In all 
three cell lines FLU showed a concentration and time-dependent cytotoxicity.  
In A-375 cells, the earliest statistically significant observable inhibition of viability 
and proliferation was seen after treatment with 5 µM FLU (24 hours of exposure). After 
48 hours treatment interval, the inhibitory FLU cone tration was 1 µM and at 72 hours 




Figure 11 - Proliferation of A-375 cells treated with flubendazole (FLU) at concentration range 0.01 -10 µM as measured by 
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In the employed experimental conditions, BOWES cellline proved to be of different 
sensitivity. After 24 hours of exposure, the first statistically significant inhibition 
occurred with 1 µM FLU. On the other hand, during longer treatment intervals of 48 
hours and 72 hours, the inhibitory FLU concentration was lower and corresponded to 
0.5 µM (Fig. 12). 
 
 
Figure 12 - Proliferation of BOWES cells treated with flubendazole (FLU) at concentration range 0.01 -10 µM as measured 




The sensitivity of RPMI-7951 cells to FLU treatment did not significantly differ 
from the one verified with other two tested cell lines (A-375 and BOWES). Still, while 
FLU at the concentration of 0.5 µM markedly suppressed viability and proliferation of 
these melanoma cells at 72 hours of treatment only,the concentration of 1 µM proved to 
be cytotoxic at both earlier time intervals (i.e. 24 hours and 48 hours) (Fig. 13). 
 
 
Figure 13 - Proliferation of RPMI-7951 cells treated with flubendazole (FLU) at concentration range 0.01 - 10 µM as 
measured by WST-1 assay. The data represent mean ± SD from three independent experiments. ** P < 0.01, *** P < 0.001, 
**** P < 0.0001 
 
 
Subsequent experiments using xCELLigence system confirmed these observations 
and helped to determine FLU IC50 values for each model cell line: A375 - IC50 = 
0.96 µM (Fig. 14A), BOWES - IC50 = 0.90 µM (Fig. 14B) and RPMI-7951 - IC50 = 
0.25 µM (Fig. 14C). In view of these results, the FLU concentration of 1 µM was used 





Figure 14 - Proliferation of A-375, BOWES and RPMI-7951 cells exposed to flubendazole (FLU) as measured by real-time 
xCELLigence system. The arrow represents the treatment after 24 hours of proliferation. 
 
7.2. Antiproliferative effects of FLU in normal human melanocytes 
Prior to further studies into the mechanisms of cytotoxicity of FLU in the employed 
melanoma cell lines, the potential cytotoxic effects of the chosen 1 µM FLU 
concentration were assessed in normal human melanocytes HEM-LP.  
 
7.2.1. Basic growth characteristics of HEM-LP 
Human epidermal melanocytes HEM-LP have typical melanocyte morphology, i.e. 
a multipolar shape with numerous spike-like extensio , larger nuclei and less 
conspicuous lysosomes and melanosomes. They grow as adherent cells in 
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a multi-layered fashion and show motile activity. Their proliferation and cycling are 
slow (population doubling occurs in the range of 4 and more days) and clearly depend 
on several factors such as seeding density as confirmed by our initial observations using 
WST-1 assay and time-lapse studies (Fig. 15).  
 
 
Figure 15 - Proliferation of HEM-LP cells as measured by WST-1 assay. The data represent mean ± SD from three independent 
experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 
 
7.2.2. Cytotoxicity of FLU on HEM-LP 
Due to the slow growth and proliferation of HEM-LP cells with further dependence 
on cell seeding density, which could produce potentially inconsistent data from WST-1 
assay, we chose to evaluate FLU effects on these cells using a direct microscopy-based 
software aided cell counting. In control cultures, the entire population doubling did not 
occur during the followed 96 hour interval; however, a steady increase in the number of 
cells was noted which was most dramatic during 24-48 hours interval. The addition of  
1 µM FLU resulted in a decreased rate of cell proliferation observable throughout the 
entire treatment period. Similar trend albeit with a lesser proliferation suppression in 
HEM-LP cells was also recorded in case of lower FLU concentration of 0.5 µM (Fig. 
16). 
On a qualitative level, the addition of 1 µM FLU produced an immediate change in 
HEM-LP morphology and behaviour. Cells rapidly retrac ed their extensions, became 
more flattened and filled up with numerous small vesicl s resembling vacuoles. Some 
of them underwent rapid shrinkage and degradation, in particular during first 12-24 
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hours of exposure. The rate of cell demise was not; however, too high and most exposed 
cells survived and continued in their existence. During later treatment periods (72–96 
hours), exposed cells started to gradually change aain back to their original 
morphological appearance and behaviour. This transitio  was accompanied by partial 
disappearance of cytoplasmic vesicles, resumed motile activity and overall patterning of 
cell population (Fig. 17). These data collectively demonstrate that FLU at the 
concentration of 1 µM has some cytotoxic and cytosta ic effects in normal human 
dermal melanocytes HEM-LP but these effects seems to lessen during the time and most 




Figure 16 - Proliferation of HEM-LP cells exposed to differing concentrations of flubendazole (FLU) during 96 hours as 

















7.3. Effects of FLU treatment on cell cycle distribution 
Flubendazole at the concentration of 1 µM showed antiproliferative effects in the 
employed melanoma cell lines while its cytotoxicity was much better tolerated in 
normal melanocytes. Thus to gain further insight ino mechanisms underlying 
FLU-dependent cytotoxicity in melanoma cells, cell cycle analysis with help of flow 
cytometry was next carried out. In FLU-exposed cell populations, as early as at 
12 hours after the beginning of treatment, significant changes in particular cell cycle 
phases were recorded when compared to controls. While individually varying, these 
changes were still present in all three tested cell lin s. Universally, both G1 and S phase 
cells declined in their numbers, with a marked increase in G2/M fraction cells (Fig. 
18B). This trend continued into 24 hours treatment interval and resulted in the majority 
of cells accumulated in G2/M phase. In A-375 cell line 79 % of cells were accumulated 
in G2/M phase, while only 2 % in G1. In BOWES cell line 75 % cells were in G2/M 
and only 9 % in G1 and in RPMI-7951 cell line 71 % of cells were in G2/M phase and 
15 % in G1 phase (Fig. 18A). Furthermore, another independent analysis using EdU 
labelling assay demonstrated that FLU treatment had a similarly severe effect on S 
phase cells too. In A-375 cell line S phase cells dropped to 8 % compared to 
approximately 50 % in controls, in BOWES cell line S phase cells dropped to 11 % 
compared to approximately 40 % in controls. In RPMI-7951 only S phase cells numbers 
were reduced to just 25 % compared to approximately 45 % in controls; however, even 
this difference was statistically significant (Fig. 19).  
 
7.4. Effects of FLU treatment on cell cycle inhibition 
In order to verify the molecular nature of our observed G2/M phase block in 
melanoma cells induced by 1 µM FLU, an analysis of cell-cycle inhibitors expression 
was carried out. Out of all potential cell cycle inhibitors belonging to INK4 and 
CIP/KIP protein families, the expression of p21 inhibitor protein was selected due to its 
role in both G1 and G2/M induced cell cycle blocks. Immunofluorescent detection of 
p21 protein in control cells revealed its weak presence and expression namely in the 
nuclei of melanoma cells. Treatment with 1 µM FLU induced increased expression of 
p21 as evident from its positive staining in the trea ed cell nuclei as well as cytoplasms 
at both time intervals of 12 hours and 24 hours. This effect was universal and no 
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quantitative as well as qualitative changes in the p21 protein presence were noted in all 
the employed cell lines (Fig. 20). 
 
Figure 18A - Cell cycle changes in melanoma cells A-375, BOWES and RPMI-7951 exposed to 1 µM flubendazole (FLU) 
during 24 hours as measured by flow cytometry. A. A-375 at 12 hours and 24 hours treatment with FLU. B. BOWES at 12 
hours and 24 hours treatment with FLU. C. RPMI-7951 at 12 hours and 24 hours treatment with FLU. The data represent 

























Figure 19 - Percentage of S-phase cells in A-375, BOWES and RPMI-7951 cells exposed to 1 µM flubendazole (FLU) during 
24 hours as measured by EdU labelling assay. The data represent mean ± SD from three independent experiments. * P < 0.05, 





Figure 20 - Expression of p21 protein in A-375, BOWES and RPMI-7951 cells exposed to 1 µM flubendazole (FLU) during 12 hours and 24 hours as determined by 




7.5. Morphological changes in cells exposed to FLU 
All used melanoma cell lines present differing cell size and morphology. These cells 
range from smaller (A-375) to larger (BOWES, RPMI-7951), mostly with prominent 
nuclei, multiple nucleoli and irregularly arranged and organized mitochondria and 






























Figure 21 - Fluorescent labeling of mitochondria, lysosomes and nuclei in 
melanoma cell lines A-375, BOWES and RPMI-7951. Green-mitochondria, 
Red-lysosomes, Blue-nuclei. Fluorescence 600 x. Scale 5 µm. 
58 
 
Time-lapse morphological studies of 1 µM FLU exposed melanoma cells revealed 
that during first 12-24 hours of exposure cells grew and divided although less 
intensively than in controls. Approximately after 12 hours of FLU exposure, there 
appeared gradually larger cells with multiple nuclei, mainly in RPMI-7951 cultures. 
These multinuclear cells were not of the uniform diensions and their nuclei differed in 
the size, shape and numbers too (Fig. 22). The status of multinucleated cells was 
confirmed with fluorescent staining using DNA-specific dye DAPI (Fig. 23). In 
addition, at later treatment interval of 24 hours, multinucleation reached further extent 
and some cells became giant in size.  
Besides multinucleation, in A-375 and RPMI-7951 cells but very little in BOWES 
cells, the perinuclear vacuolization developed. As we could see in time-lapse records, 
these vacuolated cells persisted for another 12-24 hours and then lost their attachment 
became rounded and their membrane exhibited a series of rapidly bulging protrusions 
resembling blebs. Cell rounding and membrane blebbing lasted up to 1 hour and in most 
cases led to the final fragmentation of cell bodies into small elements. Alternatively, 
some rounded cells did not show membrane blebbing and quickly underwent fast cell 
demise without any marked morphological features (Fig. 24). The dynamics of the 
described changes in treated cells differed not only between individual cell lines but 
also among particular cells. Thus in A-375 and RPMI-7951 cell lines cell rounding, 
blebbing and fragmentation occurred asynchronously while in BOWES cell line cells 
appeared to follow individual steps more synchronously.  
Another interesting phenomenon noted in the treated cells concerned the lysosomes. 
As shown in Fig. 21 melanoma cells lysosomes are mostly found concentrated around 
the nucleus, with some of them being scattered in the periphery too. Upon exposure to 
1 µM FLU and along with changes in cell´s shape (cell rounding which occurred at 
about 24-48 hours of exposure) lysosomes grew more v luminous and became 
concentrated in the cell´s centre along with mitochondria (Fig. 25). Such lysosomal 
concentration and growth in volume was especially prominent in BOWES cells while in 



















 Figure 25 - Changes in lysosomal distribution and volume in BOWES melanoma cells treated with 1 µM flubendazole (FLU) during 36 hours. Green-mitochondria, Red-lysosomes, Blue-nuclei. Fluorescence 






7.6. Effect of FLU on cytoskeleton 
Our next efforts were aimed at investigation of thechanges in the structure and 
arrangement of FLU main cellular target – cytoskeletal microtubules. In control 
cultures, microtubules of the interphase cells were typically organized from the single 
centrosome placed near the nucleus from which individual microtubule fibers extended 
to the periphery in a sheet-like pattern. During mitosis, microtubules rearranged into 
mitotic spindle attaching and separating chromosomes and upon cytokinesis connecting 
two arising cells by midbody.  
Compared to control cultures, the number and the distribution of centrosomes in 
exposed cells after FLU treatment changed, which resulted in the presence of aberrant 
mitotic spindles and subsequent multipolar mitosis (Fig. 26). Also, microtubular 
network in interphase cells became disorganized too; microtubules were damaged and 
became compacted while losing their typical arrangement.  
In addition to altered microtubular topography, some changes in actin filaments, 
namely their concentration in the subcortical regions f the cells, were noted too. Actin 
cytoskeleton is typically placed peripherally in melanocytes, in particular being positive 
in ruffling edges. In mitosing cells, actin forms a prominent ring surrounding mitotic 
spindle. In FLU exposed cells, actin distribution and or organization were not changed 
as severely as in the case of microtubules. Still, as mentioned before its accumulation 
















Figure 26 - Normal mitotic spindle in controls vs. aberrant multipolar spindle in 1 µM 
Scale 10 µm. 
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flubendazole (FLU) treated cells after 24 hours. Blue - nuclei, Green 
 




Figure 27 - Effect of 1 µM flubendazole (FLU) treatment on interphase cells cytoskeleton at 24 hours. Blue - nuclei, Green - α-tubulin, Red - β-actin. Fluorescence 600 x. Scale 10 µm.
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7.7. Characteristics of FLU-induced cell death 
As mentioned above in the section 7.5 melanoma cells exposed to 1 µM FLU 
underwent a series of morphological changes ranging from an early slight swelling to 
loss of adherence, formation of membrane protrusions – blebs and final rounding and 
fragmentation (Fig. 28). Still, not all exposed cells displayed all these steps, which, in 
addition, occurred in the context of multinucleation and cells enlargement. Despite the 
individual differences in these morphological changes and their timing the numbers of 
thus affected cells steadily grew in all tested cell lines where their proportions remained 
similar with exception of RPMI-7951 cells at 48 hours of treatment (Fig. 29). Along 
with changes in overall melanoma cells morphology and behaviour, some other typical 
markers of apoptotic cell death were present too. They included in particular the typical 
nuclear chromatin condensation and fragmentation (Fig. 30).  
FLU-induced apoptosis was further confirmed by measurement of activity of 
selected caspases known to be typically associated with apoptosis and FLU-reported 
effects - caspase-2 and caspase-3/7. Time intervals of 12 hours, 24 hours and 48 hours 
were chosen for the measurement, using the standard luminescent assay. 1 µM FLU 
activated the caspases in all three cell lines but with a different time-course and 
efficiency. In A-375 cell line, caspase 2 and caspase 3/7 activities grew in a 
time-dependent manner, reaching their maxima at 48 hours of exposure. In BOWES 
cells the similar time dependency occurred too; however, the observed activities of 
individual caspases were lower and their dynamics varied too. Thus caspase-2 activity 
became significantly elevated at the end of the followed time interval (48 hours) 
whereas caspase-3/7 activity reached its peak already at 24 hours of exposure and 
persisted until the end of the experiment. In RPMI-7951 cell line, both caspases became 
least activated and their temporal organization differed too in comparison to the 
previous two cell lines. Caspase-2 reached the maxium activity at 24 hours of 
exposure of cells to FLU and then its activity decreased while caspase-3/7 activities 



















Figure 29 - Percentage of apoptotic cells after 24 hours and 48 hours treatment with 1 µM flubendazole (FLU) in A-375, 
BOWES and RPMI-7951 cells. The data represent the mean ± SD from three indepennt experiments. ** P < 0.01, *** P < 











Figure 31 - Activity of caspase 2 and 3/7 in A-375, BOWES and RPMI-7951 cells treated with 1 µM flubendazole (FLU) 
during 48 hours. The data, presented as percentage control cells (=100 %), represent the mean ± SD from three independent 








7.8. Effect of FLU on p53-mediated proapoptotic signalling 
Gene p53 is a canonical regulator of so called intrinsic apoptotic pathways which act 
to activate cell demise by a series of biochemically controlled steps. Although p53 is 
relatively rarely mutated in melanoma the chemoresistance of this type of malignancy is 
present in almost all of its advanced stages and may involve aberrant regulation of 
p53-dependent signalling. Since some benzimidazoles w re reported to activate cell 
death in tumor cells via TP53-controlled signalling, experiments were carried out to 
determine whether 1 µM FLU-dependent cell death proceeds via this type of signalling 
too (66). Immunoblotting analyses of p53 expression as well as selected post-translation 
modifications of TP53 (namely at Ser-15 and Ser-46) in melanoma cells exposed to  
1 µM FLU during 48 hours revealed a significant differences between tested melanoma 
cell lines. Thus on the one hand, a late (48 hours) marked increase in the TP53 protein 
abundance following the treatment with 1 µM FLU occurred in A-375 cells. 
Conversely, in BOWES cells no changes whether minor or significant were visible at all 
treatment intervals and stable TP53 protein levels were present. Moreover, in 
RPMI-7951 cells, we could not detect any TP53 protein expression in both controls and 
treated cells, which seems to confirm its already repo ted p53 null-status (67). TP53 
phosphorylations at Ser-15 and Ser-46 which are regard d as instrumental 
posttranslational modifications following DNA damage and activation of apoptosis 
were not significantly elevated in none of the tested melanoma cells. Similarly, changes 
in BAX and BCL-2 protein abundances in all treated melanoma cells were only 
marginal and not significant, suggesting that the classical TP53-BAX-BCL-2 axis was 












Figure 32 - The expression of proapoptotic proteins in melanoma cell lines A-375, BOWES and RPMI-7951 exposed to 1 µM flubendazole (FLU) as measured by immunoblotting analysis during 48 hours. 




7.9. Effect of FLU in primary melanoma explants  
During 2013-2017 period, five cutaneous melanoma samples were obtained from 
Department of Plastic surgery, Faculty teaching hospital Hradec Králové. Samples were 
evaluated by a pathologist (Fig. 33) and then used for establishment of melanoma 
explant cultures in our laboratory, following the specified protocol. Resulting 
cultivations were in individual samples quite heterogeneous, containing varying 
proportions of mostly fibroblasts, melanocytes and other cells of oscillating size and 
behaviour (Fig. 34). With respect to such heterogeneity, both in terms of individual cell 
types and their characteristics, and taking into consideration cultivation success, one 
sample (M-170202) was selected to be used in pilot testing.  
Cytotoxicity of FLU (range of original concentrations) in melanoma cells obtained 
from a primary explant isolated from a patient was evaluated using WST-1 assay. The 
results of this experiment showed a similar inhibitory effect of FLU compared to our 
employed melanoma cell lines A-375, BOWES and RPMI-7951, with 1 µM FLU being 
efficient already after 24 hours of exposure (Fig 35). Conversely, unlike in melanoma 
cell lines where this FLU concentration produced a consistently increasing inhibitory 
effect in time (the most significant inhibition occurred at 72 hours of exposure), in case 
of the investigated melanoma explant the FLU-dependent inhibition remained the same 
during 72 hours treatment. In addition, FLU IC50 value (as determined by GraphPad 
Prism Software) at 72 hours equalled to 1.42 µM; i.e. a markedly higher value than the 
one obtained from stabilized melanoma lines. 
Cytometric studies of melanoma cells obtained from the melanoma explant showed 
that cells grew somewhat slower compared to the melanoma cell lines and typically 
varied in their size and appearance. When exposed to 1 µM FLU; i.e. sub IC50 dose, 
they responded by changing their internal organization which became often clumped 
into reticular-like formation. Furthermore, they developed larger vacuoles or vacuole-
like structures and gradually displayed an altered adherence pattern. Conversely, unlike 
in thus treated melanoma cell lines, giant, multinucleated cells have not formed. During 
later treatment periods (24-48 hours), cells started to shrink, sometimes slowly or 
rapidly extending their cytoplasmic membranes (Fig. 36). Subsequently observed cell 
demise was generally much less homogeneous then in the treated melanoma cell lines 
and comprised at least three distinct patterns – 1) individual cell shrinkage accompanied 
by plasma membrane undulation, 2) collective rapid shrinkage without any marked cell 
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Figure 33 – Basic histopathological characteristics of obtained human melanoma samples as provided by The Fingerland Department of pathology Faculty teaching hospital Hradec Králové.  
T-size and extend of primary tumor * 
NX - cancer in nearby lymph nodes cannot be measured * 
MX - metastatis cannot be measured * 
(*Staging. National Cancer Institute [online]. Available from: https://www.cancer.gov/about-cancer/diagnosis-staging/staging) 
 
Sample No. Gender Age 
(years) 
Tumor type Classification 
 
    Breslow         Clark                MKNO                    TNM 
M - 130328 Male 53 Nodular malignant skin melanoma 9 mm II 8721/33 pT4b, pNX, pMX 
M - 141022 Female 61 Lentigo maligna skin melanoma 0.25 mm III 8742/32  pT1a 
M - 150325 Male 52 Nodular malignant skin melanoma 2.2 mm IV 8721/32 pT3b, pNX, pMX 
M - 160121 Female 72 Nodular malignant skin melanoma 1,9 mm III 8721/33 pT2b, pNX, pMX 
















Figure 35 - Proliferation of  M-170202 treated with flubendazole (FLU) at a concentration range 0.01 - 10 µM using WST-1 













Figure 36 - Morphological changes in explant-derived melanoma cells treated with 1 µM flubendazole (FLU) after 48 hours. 




Malignant melanoma represents a relatively rare but very dangerous form of skin 
malignancy which is at its advanced stage characterized by an aggressive growth with 
the high propensity for metastatic spread and chemor sistance. Accordingly, no 
effective cytotostatic treatment of advanced malignnt melanoma is currently available 
and new targeted therapies show only limited clinical efficiency upon life-long burden 
(33). Thus continuing studies of melanoma biology are aimed at identification of novel 
putative targets in malignant melanocytes, which could be used for development of 
effective treatments. Alternatively, via revisiting already established therapeutical 
concepts the scientific efforts endeavour to find their new applications for the future 
treatment of this malignancy (45).  
One of traditional and yet novel targets in malignant cells is cytoskeleton, and 
namely microtubules. Microtubules are the major cytoskeletal components in all 
eukaryotic cells where they play a substantial rolein various processes such as mitosis, 
intracellular transport and signalling or maintenance of cell shape and polarity (68). In 
particular, during cell division, microtubules form the mitotic spindle which has become 
an essential target for the chemotherapeutic approach in a wide spectrum of 
malignancies. The effectiveness of microtubule-targetin  drugs has been validated by 
the successful use of several vinca alkaloids and txanes for the treatment of several 
human cancers. Their clinical success has prompted a worldwide search for compounds 
with similar mechanisms of action but improved characteristics, mainly due to the 
prevailing existence of toxic side-effects and develop d chemoresistance (69, 70).  
At the end of the last century, first experimental studies were published 
demonstrating cytotoxicity of selected benzimidazole carbamates (i.e. albendazole and 
mebendazole) in several cancer models (57, 66, 71-74). Although originally approved 
for treatment against parasitic worms both in humans s well as in animals, their 
selective targeting of microtubules quickly prompted scientific inquiry into their 
possible utility as antiproliferative agents (57, 66, 71-74). 
The first report on antitumor activity of FLU concern d its effects against leukaemia 
and myeloma cells where low FLU concentrations induce  mitotic catastrophe and cell 
death in malignant cells and delayed tumor growth in vivo. Still more importantly, in 
cells resistant to vinblastine due to overexpression of P-glycoprotein sensitivity to FLU 
was retained (75). In the subsequent studies carried out on several breast cancer cell 
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lines (MDA-MB-231, BT-549, SK-BR-3 and MCF-7) and panels of colon cancer as 
well as neuroblastoma cell lines, FLU displayed its broad suppressive activity via 
diverse mechanisms (76, 77). 
Based on these previously published experiences with FLU, in our present work we 
wanted to investigate the potential cytotoxic activity of FLU in an in vitro model of 
human skin melanoma using firstly several established melanoma cell lines with diverse 
molecular phenotypes. The employed cytotoxicity assay  measuring distinct endpoints 
showed that predictably FLU inhibited cell growth and proliferation of all used 
melanoma cell lines, however, with a time and concentration dependence. In addition, 
the existence of varying sensitivity of exposed cells (as indicated by particular achieved 
IC50 values) most probably reflected an inherent heterogeneity of response among 
individual cell lines which was already demonstrated with other benzimidazole 
derivatives and melanoma cell lines (72). Based on these initial experiments, we chose 
1 µM concentration of FLU for further testing in melanoma cells while verifying its 
effect on normal human skin melanocytes. Our results indicate that FLU had cytostatic 
effect in these cells as judged from their rapid morph logical changes (i.e. flattening 
and spreading), slowed growth and at least initially increased cell demise. On the other 
hand, these adverse changes lessened over the later time periods (48 hours and onward) 
and during this time interval some exposed melanocytes resumed their dynamics and 
proliferation. Thus it would seem that the employed 1 µM FLU is in this model of 
normal skin cells sufficiently tolerated. Nevertheless, at the same time one must be 
aware that this “tolerance” might be due to the rather special status of melanocytes. 
Melanocytes are responsible for melanin synthesis in the skin and as such they are 
highly resistant against environmental stresses and apoptosis, namely one induced by 
UV. Their tolerance to FLU therefore needs to be confirmed and compared with other 
skin cells (fibroblasts or keratinocytes) to verify whether normal skin would not be 
more seriously affected by this type of compound. 
To further identify the mechanisms of FLU cytotoxicity in tested melanoma cell 
lines, we next carried out cell cycle analysis, which revealed that in treated cell 
populations FLU significantly increased G2/M fraction cells upon corresponding 
decrease of the G1 phase and S phase cells. This G2/M phase arrest seems to be 
characteristic of many benzimidazole carbamate actions n tumor cells as it was also 
observed in albendazole-treated liver cancer and colon cancer cells and FLU-exposed 
colon cancer cells (56, 66).  
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As well as suffering the specific cell cycle arrest, FLU-treated melanoma cells 
further underwent a series of morphological changes which differed in their 
spatiotemporal organization and included: 1) early intracellular vacuolization, cell 
enlargement, coarsening of the cytoplasm and multinucleation and 2) later loss of 
adherence, cell rounding, cell volume shrinkage and membrane blebbing. Of all present 
changes, intracellular vacuolization was noted only sporadically in some exposed cells 
of BOWES cell line only. Specific staining subsequently revealed that vacuoles were 
accumulating and enlarged lysosomes concentrating around cell nuclei together with 
clumped mitochondria, owing most probably to the collapsing microtubular network. 
Whether thus changed lysosomal compartment lost its integrity and contributed to the 
lysosomal cell death of individual cells was not further verified. Still, induced vacuolar 
stress leading to autophagy via ROS or other more specific mechanisms was already 
reported in MDA-MB-231 breast cancer cell line treaed with FLU (55). Furthermore, a 
very recent report brought evidence of autophagy in HCT-116 colon cancer cells in 
which mitotic catastrophe was induced by doxorubicin. Authors concluded that mitotic 
catastrophe induction leads firstly to autophagy with subsequent apoptosis and the 
balanced interplay between these two processes is determined by mitotic catastrophe 
intensity (61). It seems, however, that this form of cell demise was only incidental upon 
current treatment conditions and thus its role was minor. Conversely, emergence of 
giant multinucleated cells was nearly universal in our model and clearly associated with 
the primary target of FLU in exposed cells – microtubules. FLU modifies microtubule 
structure and inhibits tubulin polymerization by interacting with a site on β-tubulin 
similar to colchicine but distinct from vinca alcaloids (75). Accordingly, in our model 
melanoma lines FLU altered microtubular cytoskeleton in dividing cells with an 
increased presence of aberrant multipolar spindles and abnormal mitosis. In addition, in 
interphase cells FLU produced visible alterations i microtubular topography too. 
Together these results suggested the presence and activation of the process called 
mitotic catastrophe.  
Mitotic catastrophe was historically first described as the process of microtubule 
disintegration (78). Nowadays, this term often denotes a mechanism of a delayed cell 
death associated with mitosis. On the other hand, several reports argue for an alternative 
view of mitotic catastrophe, which is presented as a process resulting from aberrant 
mitosis and leading to cell death – apoptosis or necrosis (79, 58). Since mitotic 
catastrophe may be induced not only by mitotic/spindle inhibitors but also by DNA 
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damaging agents, inhibited mitotic proteins or via replication fork stress, it shows a 
number of morphological and biochemical characteristics (58). In our FLU-treated 
melanoma cells, several of these characteristics were present such as persistent G2/M 
phase block, the overexpression of cell cycle inhibitor p21, multinucleation of cells and 
elevated activity of caspase-2, which clearly demonstrates the activation of this process. 
Interestingly, mitotic catastrophe has also been described to be accompanied by 
chromatin condensation, mitochondrial release of proa optotic cytochrome c and 
apoptosis inducing factor (AIF), caspase activation and DNA degradation (79), i.e. 
features typical of apoptosis implying a tight linkage between both processes. Our 
obtained results confirm this linkage since FLU-exposed melanoma cells ultimately 
showed typical apoptotic morphologies with membrane blebbing and nuclear chromatin 
condensation. To this effect, we have also verified apoptosis by detecting increased 
activity of caspase-3/7.  
Mitotic arrest and catastrophe are strongly associated with apoptosis but the exact 
molecular mechanisms of this association remain unclear. Two proposed schemes 
include both p53-independent and p53-dependent events despite the fact that multiple 
lines of evidence argue for the important role of p53 (80). Despite already reported FLU 
capacity to induce p53-dependent apoptosis in neuroblastoma cells (77), our data 
obtained from treated melanoma cells argue differently. FLU induced increased 
expression of TP53 in A-375 cell line only. Moreover, concomitant TP53 
phosphorylation concerned Ser-15 (i.e. modification enhancing TP53 accumulation) but 
not Ser-48 (i.e. modification regulating the ability of this protein to induce apoptosis), 
suggesting the non-direct involvement of this protein in induced apoptosis (81). Further 
to this, elevated activity of caspase-2 in our exposed cells hint at p53-independent 
apoptosis since this conserved initiator caspase ha been previously implicated both in 
mitotic cell death as well as mitotic catastrophe, via MOMP-dependent and p53-
independent process (82). 
 The activity of the BCL-2 protein family is a key determinant of fate following 
mitotic catastrophe (83-87). The family consists of multidomain prosurvival proteins 
(BCL-2, BCL-XL, BCL-W, MCL1, A1, and BCL-B) and multidomain proapoptotic 
effector proteins (BAX, BAK, and BOK) as well as BH3-only proteins (BIM, PUMA, 
BAD, NOXA, BIK, HRK, BMF, and tBID) (87). The multidomain members of the 
family (the prosurvival proteins and the effectors BAK, BAX, and BOK) contain four 
BCL-2 homology regions (BH1–BH4), whereas the BH3-only proteins contain only 
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a BH3 domain, which is important in mediating their interaction with the multidomain 
members. Out of them, BCL-2 protein is widely expressed in human melanoma and has 
been linked to melanoma chemoresistance through its antiapoptotic function (88). It has 
been reported that mebendazole, a benzimidazole derivate related to FLU, inhibits 
melanoma cellular proliferation through a BCL-2–mediated cellular response to 
microtubular damage (72). Furthermore, mebendazole-mediated inhibition 
of melanoma growth in vivo is accompanied by phosphorylation of BCL-2 and 
decreased levels of X-linked inhibitor of apoptosis (XIAP) via mitochondrial 
SMAC/DIABLO (81, 89).  Contrary to these findings, neither BCL-2 nor BAX proteins 
showed elevated abundances in our FLU-treated melanom  cells, implying their 
negligible role in the present apoptotic process. The lack of significant involvement of 
TP53 and selected BCL-2 family proteins in this setting prompts further questions 
concerning the exact mechanism of apoptosis activation. For instance, some of the 
relevant points to ask are: (a) Are other BCL-2 protein family members involved and to 
which extent? (b) Do mitochondria play direct role? And if so which one? (c) What is 
the mechanism of caspase-2 activation? (d) How universal is mitotic catastrophe-
apoptosis induced by FLU in melanoma types? These and other questions will no doubt 
need to be addressed in future to provide mechanistical basis for further preclinical and 
clinical testing of FLU in melanoma.  
 To provide some initial information on this matter, the above-mentioned ability 
of FLU to inhibit growth and proliferation of melanoma cells while inducing their 
mitotic catastrophe and apoptosis was tested in cells d rived from a melanoma explant 
culture established from human melanoma excisions. As explained in the Results 
section, all five samples of malignant melanoma were of differing histopathological 
grade and comprised several cell types at various initial proportions and biological 
properties. Their detailed characterization and sorting was not a primary objective of the 
present work, however, and thus resulting primary cultivations contained a mix of 
cellular phenotypes which in our opinion reflects more accurately on real tumor 
composition. Based on the growth and cultivation characteristics of cells of all samples 
one was ultimately chosen for pilot testing. These cells were firstly maintained upon 
standard laboratory conditions to verify their growth and proliferative characteristics 
and then exposed to a range of FLU concentrations t determine its effects. Similarly to 
stabilized melanoma cell lines, FLU induced time and concentration-dependent 
inhibition of growth and proliferation of melanoma cells, however, its potency was 
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lower as also judged from higher IC50 value. In addition, time-lapse morphological 
studies of treated melanoma cells revealed an entirely different FLU effect; i.e. cells 
have practically failed to form giant multinucleated structures, changing instead from 
inside out and forming areticular-like structure in their cytoplasm followed by internal 
implosion. The presence of classical, morphologically distinct apoptosis was very low 
and cells often quickly shrank, resembling necrosis-like bodies. These observations are 
on the one hand startling since to our best knowledge they have never been reported in 
benzimidazole treatment systems. On the other hand, it has been proposed that induced 
mitotic catastrophe might act as a prestage to apoptosis or necrosis (58), which could be 
this case. Since we had no further data we cannot confirm this possibility although 
several morphological indices seem support it and further inquiry into this phenomenon 

















Our research was focused on investigation of biologcal activities and in particular 
antiproliferative potential of benzimidazole carbamate derivative FLU in the in vitro 
model human skin melanoma. Concerning our original aims we have reached the 
following conclusions: 
 
1. In the human malignant melanoma cell lines of differing molecular profile 
(A-375, BOWES and RPMI-7951) FLU shows time and concentration 
dependent cytotoxity during up to 72 hours of exposure. The FLU cytotoxity 
varies among individual treated cells and is reflected with particular determined 
IC50 values (A375 - IC50 = 0.96 µM, BOWES - IC50 = 0.90 µM and RPMI-7951 
- IC50 = 0.25 µM).   
 
2. FLU concentration of 1 µM as chosen for further testing has a cytostatic rather 
than cytotoxic effect in normal human skin melanocytes. In these cells FLU 
induces morphological changes, slows proliferation a d causes limited 
activation of cell death. The observed effects are tim -limited, however, and at 
the end of the testing time period they start to abate. It is thus concluded that 
FLU exposure is at least in melanocytes tolerated. 
 
3. 1 µM FLU induces in exposed melanoma cell lines G2/M phase block, increases 
the expression of cell cycle inhibitor p21 and produces a series of morphological 
changes including formation of giant multinucleated cells as well as vacuolated 
cells. FLU interacts with microtubules of both diviing and interphase cells and 
is responsible for starting the process of mitotic catastrophe. FLU-simulated 
mitotic catastrophe leads to apoptosis in exposed mlanoma cells characterized 
by increased activities of caspase-2 and -3/7 and typical nuclear and membrane 
morphologies. Neither TP53 nor BAX or BCL-2 proteins are directly and 
universally involved in FLU-dependent apoptosis andthus further inquiries into 





4. Explant cultures of five human excised melanomas of differing histopathological 
grade were established to allow for their FLU-sensitivity testing. Due to their 
heterogeneity and varying biological properties only cells derived from one 
sample were used for pilot testing. Their sensitivity to FLU proved to be lower 
than in stabilized melanoma cell lines (IC50 = 1.42 µM). When exposed to  
sub IC50 dose of 1 µM FLU melanoma cells slow their growth and display a 
series of distinct morphological changes dissimilar to the ones observed in 
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